γδ T Cell Immunotherapy-A Review.
γδ T Cell Immunotherapy-A Review.
复制标题
DOI：
10.3390/ph8010040
复制
发表时间：
2015-02-12
期刊：
影响因子：
--
通讯作者：
Tanaka Y
中科院分区：
文献类型：
--
作者：
Kobayashi H;Tanaka Y
在过去的十年中，已经开发了利用Vγ 9VS 2 T细胞的癌症免疫疗法。已经对各种类型的实体瘤以及血液恶性肿瘤进行了大量的临床试验。基于Vγ 9VS 2 T细胞的免疫疗法可以基于这些细胞的活化和扩增的方法分为两类。尽管通过磷酸化抗原或含氮双膦酸盐（N-bis）在体内扩增Vγ 9VS 2 T细胞已被转化为早期临床试验，其中证实了治疗的安全性，但诸如活化诱导的Vγ 9VS 2 T细胞无反应性和输注这些刺激剂后外周血Vγ 9VS 2 T细胞数量减少等问题尚未得到解决。此外，难以从外周血Vγ 9VS 2 T细胞的初始数量减少的晚期癌症患者离体扩增Vγ 9VS 2 T细胞。本文综述了近年来以Vγ9Vδ2 T细胞为靶点的肿瘤免疫治疗的临床研究和报道，并对Vγ9Vδ2 T细胞为靶点的肿瘤免疫治疗的发展和完善进行了探讨。
Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy.